Home | Business News | Browse by Publication | P | Pharma Marketletter

FDA clears Biovail's Cardizem LA for the treatment of angina.

Publication: Pharma Marketletter
Publication Date: 12-APR-04
Format: Online - approximately 284 words
Delivery: Immediate Online Access
Full Article Title: FDA clears Biovail's Cardizem LA for the treatment of angina.(Brief Article)

Article Excerpt
The US Food and Drug Administration has approved the use of Canada-based Biovail's hypertension drug, Cardizem LA (diltiazem), for the treatment of chronic stable angina.

Clinical evidence

The company filed the supplemental New Drug Application last year (Marketletter July 14, 2003) which was based on findings from a randomized,...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Pharma Marketletter
Sandoz launches generic Rebetol.(Brief Article), April 12, 2004
Memory Pharma gets Nasdaq listing.(Memory Pharmaceuticals Inc.)(Brief ..., April 12, 2004
Indevus and Pliva to co-promote Sanctura.(Brief Article), April 12, 2004
Arrow to market KV's Gynazole in Australia and NZ.(Brief Article), April 12, 2004

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.